Several clinical trials are already evaluating AURK (NCT03216343, NCT03092934, NCT02719691, NCT02134067, NCT01118611) and CHK1 (NCT02735980, NCT02797964, NCT02797977, NCT02873975) inhibitors either as single agents or in combination with chemotherapy in SCLC patients. Here, CHEK1 is linked to small cell lung carcinoma.